Clinical Trial: A Phase 1 Trial to Evaluate the Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of VIS171 in Participants With Autoimmune Disease(s)

U.S., Jan. 30 -- ClinicalTrials.gov registry received information related to the study (NCT06799520) titled 'A Phase 1 Trial to Evaluate the Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of VIS171 in Participants With Autoimmune Disease(s)' on Jan. 23.

Brief Summary: The purpose of this trial is to measure safety and tolerability of subcutaneous (SC) VIS171 in combination with standard of care in participants with autoimmune disease(s). The total duration of the clinical trial for each participant will be up to approximately 9 to 12 months.

Study Start Date: Jan., 2025

Study Type: INTERVENTIONAL

Condition: Systemic Lupus Erythematosus (SLE) Alopecia Areata (AA) Immune-mediated Focal Segmental Glomeruloscl...